gallbladder removal glp 1 GLP-1 After | Safety Guide Gallbladder Risks with GLP-1 Weight

Combined global sales of GLP-1 RAs exceeded tens of billions in 2025, fueling massive profitability for the developers

That includes patients with severe obesity, significant metabolic disease, or a history of losing and regaining weight repeatedly

market. Novo alleged that Hims & Hers has continued to mass compound injectable versions [of Novos Wegovy (semaglutide)] made with inauthentic API and further engaged in promotional campaigns suggesting its compounded semaglutide products compare to the safety and efficacy of Novos Wegovy products putting patient health and wellbeing at risk. Novo further cited FDAs February 6 statement

But its a narrow one, and understanding exactly who it helps, and who it leaves out, matters just as much as the headline

Once reconstituted with bacteriostatic water, refrigerate at 28C and use within approximately 14 days